AU2023275937A1 - Peptides and methods for use in treating pain - Google Patents

Peptides and methods for use in treating pain Download PDF

Info

Publication number
AU2023275937A1
AU2023275937A1 AU2023275937A AU2023275937A AU2023275937A1 AU 2023275937 A1 AU2023275937 A1 AU 2023275937A1 AU 2023275937 A AU2023275937 A AU 2023275937A AU 2023275937 A AU2023275937 A AU 2023275937A AU 2023275937 A1 AU2023275937 A1 AU 2023275937A1
Authority
AU
Australia
Prior art keywords
seq
peptide
peptides
pain
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023275937A
Other languages
English (en)
Inventor
Stéphane GAILLARD
Abdelaziz MOQRICH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tafalgie Therapeutics
Original Assignee
Tafalgie Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tafalgie Therapeutics filed Critical Tafalgie Therapeutics
Publication of AU2023275937A1 publication Critical patent/AU2023275937A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2023275937A 2022-05-25 2023-05-25 Peptides and methods for use in treating pain Pending AU2023275937A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22305773.8 2022-05-25
EP22305773 2022-05-25
PCT/EP2023/064091 WO2023227731A1 (en) 2022-05-25 2023-05-25 Peptides and methods for use in treating pain

Publications (1)

Publication Number Publication Date
AU2023275937A1 true AU2023275937A1 (en) 2024-12-12

Family

ID=81975215

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023275937A Pending AU2023275937A1 (en) 2022-05-25 2023-05-25 Peptides and methods for use in treating pain

Country Status (12)

Country Link
US (1) US20250213654A1 (cg-RX-API-DMAC7.html)
EP (1) EP4531886A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025519127A (cg-RX-API-DMAC7.html)
KR (1) KR20250017221A (cg-RX-API-DMAC7.html)
CN (1) CN119730868A (cg-RX-API-DMAC7.html)
AR (1) AR129441A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023275937A1 (cg-RX-API-DMAC7.html)
CA (1) CA3253053A1 (cg-RX-API-DMAC7.html)
IL (1) IL317048A (cg-RX-API-DMAC7.html)
MX (1) MX2024014419A (cg-RX-API-DMAC7.html)
TW (1) TW202409064A (cg-RX-API-DMAC7.html)
WO (1) WO2023227731A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026119985A1 (en) * 2024-12-03 2026-06-11 Tafalgie Therapeutics Peptides for use in treating wounds and inflammatory diseases
WO2026119983A1 (en) 2024-12-03 2026-06-11 Tafalgie Therapeutics Peptides for use in treating pain, wounds and inflammatory diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11514853A (ja) 1995-09-08 1999-12-21 ジエンザイム コーポレイション 遺伝子治療のための改良されたaavベクター
CN103589692B (zh) 2001-11-13 2018-07-24 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
WO2006013462A2 (en) * 2004-07-30 2006-02-09 Nsgene A/S Growth factors nsg28, nsg30, and nsg32
CN103382220A (zh) * 2012-05-03 2013-11-06 北京大学 具有抗感染、抗肿瘤活性的细胞因子fam19a4及其应用
EP2801369A1 (en) 2013-05-06 2014-11-12 Centre National De La Recherche Scientifique TAFA4 compounds and uses thereof for treating pain
CN108699604A (zh) 2016-03-08 2018-10-23 艾克斯-马赛大学 用于预测急性疼痛转变为慢性疼痛的myo1a以及myo1a用于治疗疼痛的用途

Also Published As

Publication number Publication date
AR129441A1 (es) 2024-08-28
MX2024014419A (es) 2024-12-06
IL317048A (en) 2025-01-01
KR20250017221A (ko) 2025-02-04
CA3253053A1 (en) 2023-11-30
CN119730868A (zh) 2025-03-28
TW202409064A (zh) 2024-03-01
WO2023227731A1 (en) 2023-11-30
EP4531886A1 (en) 2025-04-09
JP2025519127A (ja) 2025-06-24
US20250213654A1 (en) 2025-07-03

Similar Documents

Publication Publication Date Title
US20250213654A1 (en) Peptides and methods for use in treating pain
AU2025271034A1 (en) Engineered hemichannels, engineered vesicles, and uses thereof
US20250051395A1 (en) Peptides and methods for use in treating pain
JP7097070B2 (ja) クロライドチャネルの標的発現及びその使用方法
AU2019304569B2 (en) Treatment of neuropathy with DNA constructs expressing IGF-1 isoforms
CN114269384A (zh) 调节肉毒杆菌神经毒素作用的组合物
CA3053142A1 (en) Myomerger polypeptide, nucleic acid molecules, cells, and related methods
EP2919816B1 (en) Combination treatment for amyotrophic lateral sclerosis (als)
KR20210047891A (ko) 상추 엽록체에서 무 항생제 생물약제의 생산을 위한 조성물 및 방법
JP4581115B2 (ja) そう痒性皮膚疾患の治療又は予防剤
OA22072A (en) Peptides and methods for use in treating pain.
OA22140A (en) Peptides and methods for use in treating pain.
KR20130122927A (ko) Dkk2 단백질 또는 그 유전자를 포함하는 발기부전 예방 또는 치료용 조성물 및 그의 용도
CN117003854A (zh) 用于预防或治疗骨关节炎的蛋白组合物、mRNA组合物及用途
CN119656310B (zh) 敲低或抑制ant1的试剂在制备预防和/或治疗异位骨化的药物中的应用
CN112813063A (zh) 脂代谢紊乱动物模型构建以及利用aav-crispr/cas9的修复
Johnson et al. AAV9 gene therapy restores lifespan and treats pathological and behavioral abnormalities in a mouse model of CLN8-Batten disease
Xiao Genome Editing to Abrogate Muscle Atrophy
JP2026501737A (ja) レトロ-aav、および神経変性疾患の処置における使用
CN108018311A (zh) 通过基因编辑特异靶向肌肉组织mstn治疗恶病质
JP2026501732A (ja) キメラaavおよびその使用
JP2026501738A (ja) ニューロンプロモーターおよびその使用
BG67190B1 (bg) Анти-гама мутантен протеин срещу ендогенния човешки гама интерферон